The effect of DB-67, a lipophilic camptothecin derivative, on topoisomerase I levels in non-small-cell lung cancer cells

Cancer Chemotherapy and Pharmacology

Volumn 54, Issue 4, 2004, Pages 354-360

  Bence, Aimee K ^a   Mattingly, Cynthia A ^a   Burke, Thomas G ^b,c   Adams, Val R ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

^b Tigen Pharmaceuticals Inc   (United States)

^c University of Kentucky   (United States)

Author keywords

Camptothecin; DB 67; Resistance; Topoisomerase I

Indexed keywords

7 TERT BUTYLDIMETHYLSILYL 10 HYDROXYCAMPTOTHECIN; CAMPTOTHECIN DERIVATIVE; DB 67; DNA TOPOISOMERASE; UNCLASSIFIED DRUG;

ARTICLE; CELL CULTURE; CELL STRAIN; CYTOTOXICITY; DRUG DOSE REGIMEN; DRUG EXPOSURE; DRUG MECHANISM; DRUG RESISTANCE; DRUG SENSITIVITY; DRUG WITHDRAWAL; GROWTH INHIBITION; HUMAN; IN VITRO STUDY; LIPOPHILICITY; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; WESTERN BLOTTING;

CAMPTOTHECIN; CARCINOMA, NON-SMALL-CELL LUNG; DNA TOPOISOMERASES, TYPE I; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; LUNG NEOPLASMS; ORGANOSILICON COMPOUNDS; TIME FACTORS;

EID: 4644298384     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-004-0804-3     Document Type: Article

References (45)

1. Abbruzzese JL, Madden T, Sugarman SM, Ellis AL, Loughlin S, Hess KR, Newman RA, Zwelling LA, Raber MN (1996) Phase I clinical and plasma and cellular pharmacological study of topotecan without and with granulocyte colony-stimulating factor. Clin Cancer Res 2:1489
2. Bates SE, Robey R, Miyake K, Rao K, Ross DD, Litman T (2001) The role of half-transporters in multidrug resistance. J Bioenerg Biomembr 33:503
3. Beidler DR, Chang JY (1995) Camptothecin induction of a time-dependent and concentration-dependent decrease of topoisomerase I and its implication in Camptothecin activity. Mol Pharmacol 47:907
4. Bence AK, Mattingly CA, DeSimone PA, Doukas MA, Adams VR (2002) Evaluation of topotecan cytotoxicity and topoisomerase I levels in non-small cell lung cancer cells. Proc Am Assoc Can Res 43:1227a
5. Bjornsti MA, Benedetti P, Viglianti GA, Wang JC (1989) Expression of human DNA topoisomerase I in yeast cells lacking yeast DNA topoisomerase I: restoration of sensitivity of the cells to the antitumor drug Camptothecin. Cancer Res 49:6318
6. Bom D, Curran DP, Chavan AJ, Kruszewski S, Zimmer SG, Fraley KA, Burke TG (1999) Novel A,B,E-ring-modified camptothecins displaying high lipophilicity and markedly improved human blood stabilities. J Med Chem 42:3018
7. Bom D, Curran DP, Kruszewski S, Zimmer SG, Thompson Strode J, Kohlhagen G, Du W, Chavan AJ, Fraley KA, Bingcang AL, Latus LJ, Pommier Y, Burke TG (2000) The novel silatecan 7-tert-butyldimethylsilyl-10-hydroxycamptothecin displays high lipophilicity, improved human blood stability, and potent anticancer activity. J Med Chem 43:3970
8. Bom D, Curran DP, Zhang J, Zimmer SG, Bevins R, Kruszewski S, Howe JN, Bingcang A, Latus LJ, Burke TG (2001) The highly lipophilic DNA topoisomerase I inhibitor DB-67 displays elevated lactone levels in human blood and potent anticancer activity. J Control Release 74:325
9. Burke TG, Mi Z (1993) Preferential binding of the carboxylate form of Camptothecin by human serum albumin. Anal Biochem 212:285
10. Burke TG, Mi Z (1994) The structural basis of Camptothecin interactions with human serum albumin: impact on drug stability. J Med Chem 37:40
11. Burke TG, Munshi CB, Mi Z, Jiang Y (1995) The important role of albumin in determining the relative human blood stabilities of the Camptothecin anticancer drugs. J Pharm Sci 84:518
12. Chen AY, Yu C, Potmesil M, Wall ME, Wani MC, Liu LF (1991) Camptothecin overcomes MDR1-mediated resistance in human KB carcinoma cells. Cancer Res 51:6039
13. Chen HJ, Hwong CL, Wang CH, Hwang J (2000) Degradation of DNA topoisomerase I by a novel trypsin-like serine protease in proliferating human T lymphocytes. J Biol Chem 275:13109
14. Cory AH, Owen TC, Barltrop JA, Cory JG (1991) Use of an aqueous soluble tetrazolium/formazan assay for cell growth assays in culture. Cancer Commun 3:207
15. Danks MK, Garrett KE, Marion RC, Whipple DO (1996) Subcellular redistribution of DNA topoisomerase I in anaplastic astrocytoma cells treated with topotecan. Cancer Res 56:1664
16. D'Arpa P, Liu LF (1989) Topoisomerase-targeting antitumor drugs. Biochim Biophys Acta 989:163
17. Desai SD, Liu LF, Vazquez-Abad D, D'Arpa P (1997) Ubiquitin-dependent destruction of topoisomerase I is stimulated by the antitumor drug Camptothecin. J Biol Chem 272:24159
18. Desai SD, Mao Y, Sun M, Li TK, Wu J, Liu LF (2000) Ubiquitin, SUMO-1, and UCRP in camptothecin sensitivity and resistance. Ann N Y Acad Sci 922:306
19. Eng WK, McCabe FL, Tan KB, Mattern MR, Hofmann GA, Woessner RD, Hertzberg RP, Johnson RK (1990) Development of a stable camptothecin-resistant subline of P388 leukemia with reduced topoisomerase I content. Mol Pharmacol 38:417
20. Fu Q, Kim SW, Chen HX, Grill S, Cheng YC (1999) Degradation of topoisomerase I induced by topoisomerase I inhibitors is dependent on inhibitor structure but independent of cell death. Mol Pharmacol 55:677
21. Fujimori A, Harker WG, Kohlhagen G, Hoki Y, Pommier Y (1995) Mutation at the catalytic site of topoisomerase I in CEM/C2, a human leukemia cell line resistant to camptothecin. Cancer Res 55:1339
22. Hochster H, Liebes L, Speyer J, Sorich J, Taubes B, Oratz R, Wernz J, Chachoua A, Blum RH, Zeleniuch-Jacquotte A (1997) Effect of prolonged topotecan infusion on topoisomerase 1 levels: a phase I and pharmacodynamic study. Clin Cancer Res 3:1245
23. Hochster H, Wadler S, Runowicz C, Liebes L, Cohen H, Wallach R, Sorich J, Taubes B, Speyer J (1999) Activity and pharmacodynamics of 21-day topotecan infusion in patients with ovarian cancer previously treated with platinum-based chemotherapy. New York Gynecologic Oncology Group. J Clin Oncol 17:2553
24. Hsiang YH, Liu LF (1988) Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res 48:1722
25. Hsiang YH, Hertzberg R, Hecht S, Liu LF (1985) Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 260:14873
26. Jones CB, Clements MK, Wasi S, Daoud SS (1997) Sensitivity to camptothecin of human breast carcinoma and normal endothelial cells. Cancer Chemother Pharmacol 40:475
27. Kataoka M, Wiehle S, Spitz F, Schumacher G, Roth JA, Cristiano RJ (2000) Down-regulation of bcl-2 is associated with p16INK4-mediated apoptosis in non-small cell lung cancer cells. Oncogene 19:1589
28. Kraus-Berthier L, Guilbaud N, Jan M, Saint-Dizier D, Rouillon MH, Burbridge MF, Pierre A, Atassi G (1997) Experimental antitumour activity of S 16020-2 in a panel of human tumours. Eur J Cancer 33:1881
29. Lieber M, Smith B, Szakal A, Nelson-Rees W, Todaro G (1976) A continuous tumor-cell line from a human lung carcinoma with properties of type II alveolar epithelial cells. Int J Cancer 17:62
30. Liebes L, Potmesil M, Kim T, Pease D, Buckley M, Fry D, Cho J, Adler H, Dar K, Zeleniuch-Jacquotte A, Hochster H (1998) Pharmacodynamics of topoisomerase I inhibition: Western blot determination of topoisomerase I and cleavable complex in patients with upper gastrointestinal malignancies treated with topotecan. Clin Cancer Res 4:545
31. Mao Y, Sun M, Desai SD, Liu LF (2000) SUMO-1 conjugation to topoisomerase I: a possible repair response to topoisomerase-mediated DNA damage. Proc Natl Acad Sci U S A 97:4046
32. Murren JR, Anderson S, Fedele J, Pizzorno G, Belliveau D, Zelterman D, Burtness BA, Tocino I, Flynn SD, Beidler D, Cheng YC (1997) Dose-escalation and pharmacodynamic study of topotecan in combination with cyclophosphamide in patients with refractory cancer. J Clin Oncol 15:148
33. Pollack IF, Erff M, Bom D, Burke TG, Strode JT, Curran DP (1999) Potent topoisomerase I inhibition by novel silatecans eliminates glioma proliferation in vitro and in vivo. Cancer Res 59:4898
34. Redinbo MR, Stewart L, Kuhn P, Champoux JJ, Hol WG (1998) Crystal structures of human topoisomerase I in covalent and noncovalent complexes with DNA. Science 279:1504
35. Robey RW, Honjo Y, van de Laar A, Miyake K, Regis JT, Litman T, Bates SE (2001) A functional assay for detection of the mitoxantrone resistance protein, MXR (ABCG2). Biochim Biophys Acta 1512:171
36. Saltz L, Sirott M, Young C, Tong W, Niedzwiecki D, Tzy-Jyun Y, Tao Y, Trochanowski B, Wright P, Barbosa K, Toomasi F, Kelson D (1993) Phase I clinical and pharmacology study of topotecan given daily for 5 consecutive days to patients with advanced solid tumors, with attempt at dose intensification using recombinant granulocyte colony-stimulating factor. J Natl Cancer Inst 85:1499
37. Saltz L, Danenberg K, Paty P, Kelsen D, Kemeny N, Salonga D, Park JM, Danenberg P (1998) High thymidylate synthase (TS) expression does not preclude activity of CPT-11 in colorectal cancer (CRC). Proc Am Soc Clin Oncol 17:1080
38. Sorensen M, Sehested M, Jensen PB (1995) Characterisation of a human small-cell lung cancer cell line resistant to the DNA topoisomerase I-directed drug topotecan. Br J Cancer 72:399
39. Stewart L, Redinbo MR, Qiu X, Hol WG, Champoux JJ (1998) A model for the mechanism of human topoisomerase I. Science 279:1534
40. Sugimoto Y, Tsukahara S, Oh-hara T, Isoe T, Tsuruo T (1990) Decreased expression of DNA topoisomerase I in camptothecin-resistant tumor cell lines as determined by a monoclonal antibody. Cancer Res 50:6925
41. Takahashi M, Kigawa J, Minagawa Y, Shimada M, Sugiyama T, Yakushiji M, Terakawa N (1999) Topoisomerase I activity and response to second-line chemotherapy consisting of camptothecin and cisplatin in patients with ovarian cancer. Proc Am Soc Clin Oncol 2470
42. Tanizawa A, Beitrand R, Kohlhagen G, Tabuchi A, Jenkins J, Pommier Y (1993) Cloning of Chinese hamster DNA topoisomerase I cDNA and identification of a single point mutation responsible for camptothecin resistance. J Biol Chem 268:25463
43. Trussardi A, Poitevin G, Gorisse MC, Faroux MJ, Bobichon H, Delvincourt C, Jardillier JC (1998) Sequential overexpression of LRP and MRP but not P-gp 170 in VP16-selected A549 adenocarcinoma cells. Int J Oncol 13:543
44. Wall ME, Wani MC, Cook CE, Palmer KH, McPhail AT, Lim GA (1966) Plant antitumor agents: I. The isolation and structure of camptothecin, a novel alkaloid leukemia and tumor inhibitor from Camptotheca acuminata. J Am Chem Soc 88:3888
45. Woessner RD, Eng WK, Hofmann GA, Rieman DJ, McCabe FL, Hertzberg RP, Mattern MR, Tan KB, Johnson RK (1992) Camptothecin hyper-resistant P388 cells: drug-dependent reduction in topoisomerase I content. Oncol Res 4:481